7,113 reports of this reaction
3.5% of all BEVACIZUMAB reports
#4 most reported adverse reaction
DIARRHOEA is the #4 most commonly reported adverse reaction for BEVACIZUMAB, manufactured by Genentech, Inc.. There are 7,113 FDA adverse event reports linking BEVACIZUMAB to DIARRHOEA. This represents approximately 3.5% of all 204,762 adverse event reports for this drug.
Patients taking BEVACIZUMAB who experience diarrhoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIARRHOEA is moderately reported among BEVACIZUMAB users, representing a notable but not dominant share of adverse events.
In addition to diarrhoea, the following adverse reactions have been reported for BEVACIZUMAB:
The following drugs have also been linked to diarrhoea in FDA adverse event reports:
DIARRHOEA has been reported as an adverse event in 7,113 FDA reports for BEVACIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIARRHOEA accounts for approximately 3.5% of all adverse event reports for BEVACIZUMAB, making it a notable side effect.
If you experience diarrhoea while taking BEVACIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.